AUTHOR=Zhang Luming , Wang Zichen , Xu Fengshuo , Ren Yinlong , Wang Hao , Han Didi , Lyu Jun , Yin Haiyan 

TITLE=The Role of Glucocorticoids in the Treatment of ARDS: A Multicenter Retrospective Study Based on the eICU Collaborative Research Database

JOURNAL=Frontiers in Medicine

VOLUME=Volume 8 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.678260

DOI=10.3389/fmed.2021.678260

ISSN=2296-858X

ABSTRACT=Background: Acute respiratory distress syndrome (ARDS) are common causes of respiratory failure in intensive care unit (ICU) patients. The therapeutic value of glucocorticoids (GCs) in the prognosis of ARDS remains controversial. The aim of this research is studying the impacts of GCs treatment on ARDS patients in intensive care unit (ICU).
Methods: We retrospectively studied ARDS patients whose data were collected from the public eICU Collaborative Research Database, among which 254 patients who received glucocorticoid (GCs) treatment were 1:1 matched by propensity matching analysis (PSM). The primary outcome was ICU mortality. Every oxygenation index (PaO2/FiO2) measurement before death or ICU discharge was recorded. A joint model (JM) combined the longitudinal analysis of PaO2/FiO2 using linear mixed effect model as longitudinal sub-model and Cox regression model as time-to event sub-model based on trajectory functions was conducted to determine the effects of GCs treatment on both ICU mortality and PaO2/FiO2 level and the association between changes in PaO2/FiO2 and the event status. The marginal structural cox model (MSCM) adjusted the overall PaO2/FiO2 of patients to further validate the results.
Results: The result of the survival sub-model showed that GCs treatment was significantly associated with reduced ICU mortality in ARDS patients (HR [95% CI] =0.642 [0.453, 0.912]), demonstrating that GCs treatment was a protective factor of ICU mortality. In the longitudinal sub-model, GCs treatment was not correlated to the PaO2/FiO2. After adjusted by the JM, the HR of GCs treatment was 0.602 while GCs was still not significantly related to PaO2/FiO2 level. The JM-induced association showed that higher PaO2/FiO2 was a significant protective factor of mortality in ARDS patients and the HR was 0.991 which demonstrated that one level increase of PaO2/FiO2 level decreased 0.9% risk of ICU mortality. MSCM results also show that GCs can improve the prognosis of patients.
Conclusion: Rational use of GCs can reduce the ICU mortality of ARDS patients in ICU. In addition to the use of GCs treatment, clinicians should also focus on the shifting trend of PaO2/FiO2 level to provide better conditions for patients' survival.